MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Animals
Antineoplastic Agents, Immunological
/ administration & dosage
Cell Line, Tumor
ErbB Receptors
/ antagonists & inhibitors
Feasibility Studies
Female
Histidine
/ chemistry
Humans
Mice
Molecular Imaging
/ methods
Neoplasms
/ diagnostic imaging
Oligopeptides
/ chemistry
Organotechnetium Compounds
/ administration & dosage
Panitumumab
/ administration & dosage
Radiopharmaceuticals
/ administration & dosage
Tissue Distribution
Tomography, Emission-Computed, Single-Photon
/ methods
Tomography, X-Ray Computed
/ methods
X-Ray Microtomography
/ methods
Xenograft Model Antitumor Assays
Tc
epidermal growth factor receptors (EGFR)
head and neck squamous cell carcinoma
pancreatic cancer
panitumumab
single photon emission computed tomography (SPECT)
triple-negative breast cancer
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
05 08 2019
05 08 2019
Historique:
pubmed:
27
6
2019
medline:
26
6
2020
entrez:
27
6
2019
Statut:
ppublish
Résumé
We aimed to investigate the feasibility of conjugating synthetic hexahistidine peptides (His
Identifiants
pubmed: 31242384
doi: 10.1021/acs.molpharmaceut.9b00422
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
His-His-His-His-His-His
0
Oligopeptides
0
Organotechnetium Compounds
0
Radiopharmaceuticals
0
Histidine
4QD397987E
Panitumumab
6A901E312A
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM